Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
FAQs

Why is Early DMPK Important?

In 1991, up to 40% of failures in the clinical phase of new drug development were associated with drug DMPK properties; in 2000, the likelihood of late failure was dramatically reduced to less than 10% as major pharmaceutical companies shifted to early DMPK studies.

(1) Early pharmacokinetic testing allows for a low-cost, short-term risk-benefit assessment of new drug development projects.

(2) Guiding the processes from optimization of lead compounds to determination of preclinical drug candidates.